New Clinical Diagnostics Distributor Program Enhances EKF Customer Service

EKF Diagnostics Appoints New EMEA Distribution Manager

Cardiff, UK – 6th May 2014 – EKF Diagnostics, the global diagnostics company, today announces the introduction of the new Premium Partnership Program for its distributors worldwide, as well as the appointment of a dedicated EMEA Distribution Manager, Simona Carnielli. This significant investment into its distribution network ensures EKF Diagnostics’ customers are optimally supported on a global basis.

EKF’s Premium Partnership Program (PPP) will provide its participating distributors with unique access to EKF’s diagnostics product and specialist industry knowledge. Benefits include local training and Master Class events providing distributors and customer groups with direct access to EKF product experts. The EKF Support Centre will provide an online resource allowing distributors to access detailed information and download a range of support materials.

The Program features a rebate scheme, the Annual Growth Rebate, which will allow EKF’s distributors to collect an annual reimbursement, calculated against its increase in sales revenue from the previous year. This incentive affords the opportunity for distributors to increase their profitability, whilst driving the EKF business in its regional markets.

Further enhancing customer service in EMEA, Simona Carnielli has joined EKF Diagnostics as EMEA Distribution Manager. One of her primary responsibilities will be to implement and manage the PPP with member distributors and assist in customer support. Simona holds extensive molecular and clinical diagnostics industry knowledge, having previously worked for companies including Cepheid, Acrometrix and Abbott Diagnostics.

“EKF Diagnostics customers need to be fully supported whatever their location to ensure that they can optimally use our products at all times,” commented Simona Carnielli, Distribution Manager EMEA. “Our new Premium Partnership Program has been developed with the aim of providing concrete benefits that add value to our distributors, by supporting them with tangible tools of marketing, sales and technical material. I want to make sure they receive constant and extensive support and training to drive best practice and deliver an effective service offering to EKF Diagnostics’ end users around the globe.”

For more information on EKF Diagnostics, please visit www.ekfdiagnostics.com.

 

About EKF Diagnosticswww.ekfdiagnostics.com
EKF Diagnostics Holdings plc which includes the EKF Diagnostics, EKF Molecular, Stanbio Laboratory, Separation Technology Inc, Diaspect and Selah Genomics brands, specializes in the development, production and worldwide distribution of point-of-care blood analyzers for use in the detection and management of diabetes, anemia, lactate and kidney related diseases. Its new Molecular division focuses on molecular and companion diagnostics. EKF products are sold in more than 100 countries around the globe, offering over 30 specialist product lines across its brand portfolio.

Point-of-care diagnostics: EKF Diagnostics’ expertise covers the entire in vitro diagnostics chain, from fermentation and enzyme production, to liquid reagent manufacture, design and building of world-class diagnostic devices, and distribution of rapid test kits for infectious diseases and pregnancy. The EKF analyzer range is used widely in GP surgeries, pharmacies, blood banks, sports clinics, hospitals and laboratories for glucose, lactate, hemoglobin, hematocrit and HbA1c measurement.

Companion Diagnostics: In March 2013 EKF set up a new division to focus on molecular and companion diagnostics - EKF Molecular Diagnostics develops technologies for cancer gene detection. Through its acquisition of UK-based 360 Genomics and by offering innovative products with the potential to change current DNA extraction and detection practices, EKF is addressing the fast growing companion diagnostics market.

EKF Diagnostics’ strengths lie in its multi-national research and manufacturing facilities, teams of experienced analysts and engineers in Germany, Ireland, USA and the UK, and a board led by some of world’s foremost authorities in medical diagnostics.